MBX — MBX Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00- $306.50m
- $44.35m
Annual cashflow statement for MBX Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Net Income/Starting Line | -26.1 | -32.6 | -61.9 |
| Depreciation | |||
| Non-Cash Items | 1.67 | 1.16 | 2.4 |
| Unusual Items | |||
| Other Non-Cash Items | |||
| Changes in Working Capital | 1.29 | -0.735 | 4.6 |
| Change in Prepaid Expenses | |||
| Change in Other Assets | |||
| Change in Accounts Payable | |||
| Change in Accrued Expenses | |||
| Cash from Operating Activities | -23.1 | -32 | -54.7 |
| Capital Expenditures | -0.441 | -0.129 | -0.874 |
| Purchase of Fixed Assets | |||
| Other Investing Cash Flow Items | -11 | -30.8 | -160 |
| Sale/Maturity of Investment | |||
| Purchase of Investments | |||
| Cash from Investing Activities | -11.4 | -30.9 | -161 |
| Financing Cash Flow Items | -0.458 | -0.03 | -4.34 |
| Other Financing Cash Flow | |||
| Net Issuance / Retirement of Stock | |||
| Net Issuance / Retirement of Debt | |||
| Cash from Financing Activities | 46.1 | 69.2 | 234 |
| Beginning Cash Balance | |||
| Ending Cash Balance | |||
| Net Change in Cash | 11.5 | 6.31 | 18.8 |